NVO
AI Execution Plan
Novo Nordisk plunged 15-18% on Feb 4 after Q4 earnings revealed 2026 sales guidance of -5% to -13% decline (reversal from prior growth), CEO warns 'worse before it gets better'. Faces competition from Hims & Hers cheaper Wegovy alternative; legal action initiated. Share repurchase program announced but stock extends losses.
Strong Sell on daily timeframe: falling trend channel indicating pessimism. 5 sell signals vs 1 buy; bearish oscillators and moving averages per Investing.com and TradingView.
3-Month AI Outlook
Bearish: Weak 2026 guidance, competition in GLP-1 drugs (Ozempic/Wegovy), pricing pressures likely to pressure shares further. Potential rebound if pipeline (CagriSema) data impresses, but high risk near 52-week lows.
Option Chain
| Strike | Bid | Ask | IV % | Vol | OI | Time |
|---|
| Strike | Bid | Ask | IV % | Vol | OI | Time |
|---|
Earnings History: NVO
Strategy Overview
Jason Wheel is a systematic, AI‑enhanced trading framework built on probability theory and volatility‑based edge extraction. Designed for the US options market, the system focuses on constructing high‑probability Credit Spread strategies that capture Theta decay while maintaining strict quantitative risk controls to mitigate tail events and support long‑term, stable capital growth.
Rather than relying on directional speculation, the system operates as a closed‑loop asset engine integrating: Macro Risk Control, Multi-dimensional Quantitative Screening, AI-Assisted Decision Making, and Dynamic Position Management.
This architecture enables consistent, rules‑driven execution with an emphasis on risk‑adjusted returns.
Connect with Jason
- Substack: jasonwheel.substack.com
- Email: [email protected]